Bosutinib (BOS) and letrozole (LET) versus LET alone as first-line treatment in postmenopausal women with advanced breast cancer (ABC).
L. Chow
No relevant relationships to disclose
B. Xu
No relevant relationships to disclose
L. Y. Dirix
No relevant relationships to disclose
B. Moy
No relevant relationships to disclose
E. Leip
Employment or Leadership Position - Pfizer
N. Bardy-Bouxin
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
L. Duvillie
Employment or Leadership Position - Pfizer
T. Sarosiek
Honoraria - Pfizer
Research Funding - Pfizer